TABLE 1.
Baseline characteristics (periods)
| Baseline variable | First wave | Between‐wave | Second wave | Control period first wave | Control period second wave |
|---|---|---|---|---|---|
| (N = 108) | (N = 250) | (N = 166) | (N = 339) | (N = 455) | |
| Age, median (range) | 69 (36‐94) | 68 (22‐91) | 68 (27‐91) | 68 (21‐92) | 66 (24‐92) |
| Gender | |||||
| Male | 60 (55.6) | 148 (59.2) | 97 (58.4) | 199 (58.7) | 269 (59.1) |
| Female | 48 (44.4) | 102 (40.8) | 69 (41.6) | 140 (41.3) | 186 (40.9) |
| ECOG PS | |||||
| 0–1 | 79 (82.3) | 181 (77.7) | 109 (72.2) | 259 (85.5) | 351 (84.4) |
| ≥2 | 17 (17.7) | 52 (22.3) | 42 (27.8) | 44 (14.5) | 65 (15.6) |
| LDH | |||||
| Not determined/normal | 54 (54.0) | 133 (58.6) | 77 (50.0) | 195 (60.9) | 255 (59.7) |
| 250‐500 U/L | 29 (29.0) | 59 (26.0) | 48 (31.2) | 83 (25.9) | 100 (23.4) |
| >500 U/L | 17 (17.0) | 35 (15.4) | 29 (18.8) | 42 (13.1) | 72 (16.9) |
| Stage (8th edition AJCC) | |||||
| Unresectable IIIc | 13 (12.3) | 29 (11.9) | 9 (5.5) | 34 (10.1) | 49 (10.8) |
| IV‐M1a | 8 (7.5) | 10 (4.1) | 5 (3.1) | 31 (9.2) | 36 (8.0) |
| IV‐M1b | 11 (10.4) | 33 (13.6) | 24 (14.7) | 38 (11.3) | 44 (9.7) |
| IV‐M1c | 39 (36.8) | 96 (39.5) | 59 (36.2) | 133 (39.5) | 196 (43.4) |
| IV‐M1d | 35 (33.0) | 75 (30.9) | 66 (40.5) | 101 (30.0) | 127 (28.1) |
| Brain metastases | |||||
| No | 68 (66.0) | 163 (68.5) | 94 (58.8) | 225 (69.0) | 309 (70.9) |
| Yes, asymptomatic | 13 (12.6) | 34 (14.3) | 29 (18.1) | 36 (11.0) | 62 (14.2) |
| Yes, symptomatic | 22 (21.4) | 41 (17.2) | 37 (23.1) | 65 (19.9) | 65 (14.9) |
| Liver metastases | |||||
| No | 74 (70.5) | 180 (74.1) | 103 (64.0) | 244 (73.5) | 313 (69.7) |
| Yes | 31 (29.5) | 63 (25.9) | 58 (36.0) | 88 (26.5) | 136 (30.3) |
| Organ sites | |||||
| 0‐2 | 64 (59.3) | 140 (56.0) | 94 (56.6) | 200 (59.0) | 258 (56.7) |
| ≥3 | 44 (40.7) | 110 (44.0) | 72 (43.4) | 139 (41.0) | 197 (43.3) |
| BRAFV600‐mutation | |||||
| Wild‐type | 66 (61.1) | 130 (52.0) | 87 (52.4) | 179 (52.8) | 221 (48.6) |
| Mutant | 42 (38.9) | 120 (48.0) | 79 (47.6) | 160 (47.2) | 234 (51.4) |
| Region | |||||
| North | 15 (13.9) | 51 (20.4) | 33 (19.9) | 74 (21.8) | 90 (19.8) |
| Middle | 65 (60.2) | 139 (55.6) | 102 (61.4) | 178 (52.5) | 266 (58.5) |
| South | 28 (25.9) | 60 (24.0) | 31 (18.7) | 87 (25.7) | 98 (21.5) |
Note: Comparison of baseline characteristics of patients diagnosed in the three different period defined in our study. First wave (16 March 2020 until 24 May 2020), between‐wave (25 May 2020 until 20 September 2020), second wave (21 September 2020 until 27 December 2020) and control periods (16 March 2018 until 24 May 2018 and 16 March 2019 until 24 May 2019) for the first wave and (21 September 2018 until 27 December 2018 and 21 September 2019 until 27 December 2019) for the second wave.